Compare RXRX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXRX | DMRA |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | RXRX | DMRA |
|---|---|---|
| Price | $3.82 | $20.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.50 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 17.2M | 625.3K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.79 | ★ 121.48 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,681,000.00 | N/A |
| Revenue This Year | $12.11 | N/A |
| Revenue Next Year | $82.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.92 | N/A |
| 52 Week Low | $2.77 | $16.50 |
| 52 Week High | $7.18 | $34.89 |
| Indicator | RXRX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 28.36 |
| Support Level | $2.90 | $18.59 |
| Resistance Level | $4.05 | $26.76 |
| Average True Range (ATR) | 0.24 | 1.73 |
| MACD | 0.03 | -0.44 |
| Stochastic Oscillator | 69.16 | 10.42 |
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.